Some estimates suggest an overall 30% loss in brain GSH levels due to normal aging
It accelerates blood vessel formation (angiogenesis), modulates inflammatory pathways, and enhances collagen synthesis, all of which are crucial for tissue recovery
The Journal of Clinical Investigation, 92 (5), 2368-2376.
Both remain in phase 3 clinical development programs [16]: Cagrilintide Status: Phase 3 trials ongoing for CagriSema (cagrilintide + semaglutide combination) Expected approval timeline: 2027-2028 for the combination product Monotherapy development pathway unclear Retatrutide Status: Phase 3 trials initiated in 2024-2025 Monotherapy development for obesity and metabolic dysfunction Expected approval timeline: 2028-2029 if trials succeed This regulatory status means any use of these compounds, whether individually or in cagrilintide dosage with retatrutide combinations, occurs in research contexts or through off-label prescribing once (if) individual approvals are obtained
Cagrilintide 5 mg vial + 2.0 mL BAC 2.5 mg/mL
Retatrutide Dosage Protocols from Clinical Trials Phase 2 clinical trials published in The New England Journal of Medicine in 2023 established the foundational retatrutide dosage framework [6]: Standard Retatrutide Dosing Schedule: 4 mg weekly Lower effective dose with moderate efficacy 8 mg weekly Mid-range dose with enhanced metabolic effects 12 mg weekly Maximum studied dose achieving 24.2% mean weight reduction The 12 mg dose demonstrated the most significant metabolic effects but also carried the highest incidence of gastrointestinal adverse events, with nausea reported in 60-80% of participants [7]
